HIV-1感染者接种第二剂BNT162b2与mRNA-1273疫苗后SARS-CoV-2抗体应答比较
该观察性研究纳入119例未感染SARS-CoV-2的HIV-1感染者,分别接种两剂BNT162b2(n=91)或mRNA-1273(n=28),在接种前、第二剂后约6周和24周检测抗SARS-CoV-2刺突抗体滴度。mRNA-1273组在6周和24周抗体滴度均显著高于BNT162b2组(P<0.0001),随访期间无重症COVID-19发生。
要点
- HIV-1感染者接种两剂mRNA疫苗均产生有效体液应答。
- mRNA-1273组6周和24周抗体滴度显著高于BNT162b2组(P<0.0001)。
- 接种mRNA-1273与6周抗体≥4160 AU/mL独立相关(调整OR 24.1)。
核心结论
- BNT162b2和mRNA-1273均在HIV-1感染者中诱导有效体液应答,mRNA-1273产生显著更高且更持久的抗体滴度。
- 研究结果支持针对免疫受损人群的疫苗选择策略,并强调持续监测和考虑加强剂次的必要性。
研究设计与样本
- 观察性研究,纳入119例无既往SARS-CoV-2感染的HIV-1感染者,接种两剂BNT162b2(n=91)或mRNA-1273(n=28)。
- 在接种前、第二剂后约6周和24周检测抗SARS-CoV-2刺突抗体滴度,采用多因素logistic回归分析抗体应答相关因素。
主要发现
- mRNA-1273组在6周和24周抗体滴度均显著高于BNT162b2组(P<0.0001)。
- 接种mRNA-1273与6周抗体滴度≥4160 AU/mL独立相关(调整OR 24.1;95%CI 6.26-161)。
- 接种mRNA-1273与24周抗体滴度≥1000 AU/mL独立相关(调整OR 21.7;95%CI 6.72-85.5)。
- 与较高抗体滴度相关的其他因素包括较年轻年龄、较高CD4+ T细胞计数和无吸烟史。
- 随访期间无重症COVID-19感染发生。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with human immunodeficiency virus type 1 (PLWH) are at increased risk for severe outcomes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Although SARS-CoV-2 mRNA vaccines have demonstrated strong immunogenicity in general populations, comparative data regarding the humoral immune responses in PLWH remain limited. This study aimed to compare the humoral responses elicited by two widely used mRNA vaccines, BNT162b2 and mRNA-1273, in Japanese PLWH. METHODS: This observational study investigated 119 PLWH without prior SARS-CoV-2 infection who received two doses of BNT162b2 (n = 91) or mRNA-1273 (n = 28). Anti-SARS-CoV-2 spike antibody titers were measured at three time points: before vaccination and approximately 6 weeks and 24 weeks after the second vaccine dose. Factors associated with the antibody responses were analyzed by multivariate logistic regression. RESULTS: Both vaccines elicited robust antibody responses in PLWH, with the mRNA-1273 group having significantly higher antibody titers than the BNT162b2 group at 6 and 24 weeks (P < 0.0001). Receipt of mRNA-1273 was independently associated with antibody titers ≥4160 AU/mL at 6 weeks (adjusted odds ratio, 24.1; 95 % confidence interval, 6.26-161) and ≥ 1000 AU/mL at 24 weeks (adjusted odds ratio, 21.7; 95 % confidence interval, 6.72-85.5). Other factors associated with higher antibody titers included younger age, higher CD4+ T cell count, and absence of smoking history. Despite the differences in the antibody levels, no severe COVID-19 infections occurred during the follow-up period. CONCLUSIONS: BNT162b2 and mRNA-1273 both induce effective humoral responses in PLWH, with mRNA-1273 producing significantly higher and more durable antibody titers. The present findings support vaccine selection strategies tailored to immunocompromised populations and highlight the need for continued monitoring and consideration of booster doses.
引用
- Murata M, Matsumoto Y, Shimono N, et al. Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1. Vaccine. 2025. PMID: 40645029. doi:10.1016/j.vaccine.2025.127457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。